Views

CrossRef citations to date

Altmetric

Report

July 2017 ENCALS statement on edaravone

Ammar Al-ChalabiMaurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King’s College London, London, UK;

http://orcid.org/0000-0002-4924-7712

Peter M. AndersenDepartment of Pharmacology and Clinical Neuroscience, Umeä University, Umeä, Sweden;

Siddharthan ChandranUniversity of Edinburgh, Scotland, UK;

Adriano ChioRita Levi Montalcini’ Department of Neuroscience, ALS Center, University of Torino, Torino, Italy;

Philippe CorciaCentre de compétence SLA-fédération Tours-Limoges, CHU de Tours, Tours, France;

Philippe CouratierCentre de compétence SLA-fédération Tours-Limoges, CHU de Limoges, Limoges, Fance;

Olof DanielssonDepartment of Neurology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden;

Mamede de CarvalhoInstitute of Physiology-Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; ;Department of Neurosciences And Mental Health, H Santa Maria-CHLN, Lisbon, Portugal;

Claude DesnuelleHôpital Pasteur 2 – CHU de Nice, Nice, France;

Torsten GrehlAlfried Krupp Krankenhaus, Rüttenscheid, Essen, Germany;

Julian GrosskreutzHans-Berger Department of Neurology, Jena University Hospital, Jena, Germany;

Trygve HolmøyKershus Universitetssykehus Lørenskog, Lørenskog, Norway;

Caroline IngreKarolinska Instituted, Stockholm, Sweden;

Merete KarlsborgDepartment of Neurology, Bispebjerg Hospital, Copenhagen, Denmark;

Grethe KlevelandAvdeling for nevrologi og klinisk nevrofysiologi, Sykehuset Innlandet, Lillehammer, Norway;

Jan Christoph KochDepartment of Neurology, University Medicine Göttingen, Göttingen, Germany;

Blaz KoritnikInstitute of Clinical Neurophysiology, University Medical Centre Ljubljana, Ljubljana, Slovenia;

Magdalena KuzmaKozakiewiczDepartment of Neurology, Medical University of Warsaw, Warsaw, Poland;

Hannu LaaksovirtaHelsinki University Central Hospital, Helsinki, Finland;

Albert LudolphDepartment of Neurology, University of Ulm, Ulm, Germany;

Christopher McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK;

http://orcid.org/0000-0002-1269-9053

Thomas MeyerALS Outpatient Department, Charité – Universitä;tsmedizin Berlin, Berlin, Germany;

Bernardo Mitre RoperoSahlgrenska Universitetssjukhuset, Gothenburg, Sweden;

Jesus Mora PardinaALS Unit, Hospital San Rafael, Madrid, Spain;

Ingela NygrenUppsala University, Uppsala, Sweden;

Susanne PetriDepartment of Neurology, Hannover Medical School, Hannover, Germany;

Mónica Povedano PanadesNeurology department Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain;

Francois SalachasHôpital de la Salpêtrière, Paris, France;

Pamela ShawSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK;

http://orcid.org/0000-0002-8925-2567

Vincenzo SilaniDepartment of Neurology-Stroke Unit and Laboratory of Neuroscience, Department of Pathophysiology and Transplantation, Center for Neurotechnology and Brain Therapeutics, Università degli Studi di Milano, IRCCS Istituto Auxologico Italiano, Milan, Italy;

Gert StaafLund University, Lund, Sweden;

Kirsten SvenstrupDepartment of Neurology, Bispebjerg Hospital, Copenhagen, Denmark;

Kevin TalbotNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK;

Ole-Bjørn TysnesHaukeland universitetssjukehus, Bergen, Norway;

Philip Van DammeKU Leuven – University of Leuven, Department of Neurosciences, Experimental Neurology, Leuven, Belgium; ;VIB Center for Brain & Disease Research, Leuven, Belgium; ;University Hospitals Leuven, Department of Neurology, Leuven, Belgium;

Anneke van der KooiDepartment of Neurology, Academic Medical Centre, University of Amsterdam Center, Amsterdam, The Netherlands;

Markus WeberNeuromuscular Diseases Center/ALS Clinic, Kantonsspital St. Gallen, St.Gallen, Switzerland;

Patrick WeydtDepartment of Neurodegenerative Diseases and Gerontopsychiatry, Bonn University, Bonn, Germany;

Joachim WolfDepartment of Neurology, Mannheim, Diakonissenkrankenhaus, Mannheim, Germany;

Orla HardimanAcademic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland;

http://orcid.org/0000-0003-2610-1291

Leonard H. van den BergDepartment of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands

http://orcid.org/0000-0002-5203-9674

show all

Click to increase image sizeClick to decrease image size

Declaration of interest

The following author do not have conflict of interest: Siddharthan Chandran, Philippe Couratier, Olof Danielsson, Torsten Grehl, Caroline Ingre, Merete Karlsborg, Grethe Kleveland, Blaz Koritnik, Magdalena KuzmaKozakiewicz, Hannu Laaksovirta, Bernardo Mitre Ropero, Ingela Nygren, Mónica Povedano Panades, Francois Salachas, Gert Staaf, Kirsten Svenstrup, Kevin Talbot, Ole-Bjørn Tysnes, Patrick Weydt, and Joachim Wolf.

Ammar Al-Chalabi is consultant for Mitsubishi-Tanabe Pharma, Cytokinetics, OrionPharma, Chronos Therapeutics, Treeway, GSK, Lilly, Biogen Idec; Chief Investigator for clinical trials run by Cytokinetics, OrionPharma; speaking honoraria from Cytokinetics Inc and Lilly.

Peter M. Andersen received consulting fees from Biogen Idec and Orphazyme ApS on matters concerning clinical trials and ALS.

Adriano Chio served on an advisory panel on MITOS and KING’S for Mitsubishi Tanabe, consultant without compensation to Treeway, consultant for Biogen Idec and Italfarmaco.

Philippe Corcia is an investigator for clinical trials led by Cytokinetics, Consulting fees from Roche.

Mamede de Carvalho received consulting fees from Biogen, Merck Idec, Kedrion and Cytokinetics.

Claude Desnuelle is a consultant for EFFIK SA France, Sanofi–Genzyme Co, NanoMedSyn.

Julian Grosskreutz is consulted for Biogen.

Trygve Holmøy received consulting fees from Biogen, Merck, Genzyme and run studies without compensation for Merck and Biogen, not related to ALS.

Jan Christoph Koch is Co-PI of IIT ROCK-ALS.

Albert Ludolph is on an advisory board of Biogen, Treeway, Hoffmann-La Roche, has signed contracts for clinical Studies with AB Science, Biogen Idec, Cytokinetics, GSK, Orion Pharam, Novartis, TauRx Therapeutics Ltd. and TEVA Pharmaceuticals, consulted for Mitsubishi, Orion Pharma, Novartis, Teva.

Christopher McDermott is consultant for OrionPharma; Investigator for studies run by Biogen Idec, cytokinetics.

Thomas Meyer is consultant for Cytokinetics, GSK and Desitin Arzneimittel GmbH, founder of the internet platform Ambulanzpartner and co-owner of Ambulanzpartner Soziotechnologie GmbH.

Jesus Mora Pardina is consultant for AB-Science.

Susanne Petri is consultant for Cytokinetics, Investigator for clinical trials led by Cytokinetics, Orion Pharma, Biogen Idec, GlaxoSmithKline; speaking honoraria from Teva.

Pamela Shaw is consultant without compensation for Treeway and is a member of scientific advisory boards for Biogen, and Orion.

Vincenzo Silani received consulting fees from Mitsubishi and Cytokinetics.

Philip Van Damme received consulting fees from Mitsubishi, Cytokinetics, Biogen Idec.

Anneke van der Kooi received research grant from Behring for investigator initiated study.

Markus Weber received consulting fees from Mitsubishi, Biogen Idec, Merz Parma Schweiz, consultant without compensation to Treeway.

Leonard H. van den Berg is consultant without compensation to Treeway, LHvdb declares personal fees from Baxalta, and is a member of the Scientific Advisory Boards for Biogen Idec, Cytokinetics and Orion.

Orla Hardiman is consultant for Mitsubishi and for Treeway.

July 2017 ENCALS statement on edaravone

Information for

Open access

Opportunities

Help and information

July 2017 ENCALS statement on edaravone

Declaration of interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature